Avsar.

Consumer Discretionary · Pharmacy Retail

Medplus Health Services Ltd (MEDPLUS)

₹720.55

Mkt cap
₹9,696 Cr
P/E ratio
44.10
P/B
4.37
Div yield
0.00%
ROE
11.80%
ROCE
12.60%
EPS (TTM)
₹16.34
Book value
₹165
52W range
692–954
Sector
Consumer Discretionary

Medplus Health · Mkt Cap: 9,696 Crore (down -11.4% in 1 year) · Revenue: 6,892 Cr · Profit: 220 Cr · Stock is trading at 4.90 times its book value · Though the company is reporting repeated profits, it is not paying out dividend · Promoter Holding: 40.2%

NSE MEDPLUSBSE 543427www.medplusindia.com
Health check
Constructive
ValuationFair
ProfitabilityAverage
GrowthHigh
TechnicalsNeutral
52-week range
−24.46% from high
₹721
₹692+4.13% from low₹954
Current
₹720.55
Prev close
₹721.00
Day
−0.06%
Price performance
1D
−0.06%
1W
−10.08%
1M
−13.71%
3M
−20.26%
6M
−10.06%
1Y
−21.47%
YTD
−10.85%

Financials

F
Revenue, profit & margin
P/E ratio
44.1×
MEDPLUS is 1% below the sector median of 44.5×
MEDPLUS44.1×
Sector median44.5×
 Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Trend
Sales1,2531,2841,4091,4411,4901,4891,5761,5611,5101,5431,6791,8061,864
Expenses1,1711,2131,3241,3501,3851,3951,4521,4291,3731,4121,5301,6481,695
Operating Profit8271859210694124133136131149159169
OPM %7%6%6%6%7%6%8%8%9%8%9%9%9%
Other Income149101010912131615171821
Interest22232424252525262727293133
Depreciation56525557596063626466697376
Profit before tax1751620321848576153697380
Tax %-54%26%12%31%-5%19%19%19%16%20%19%21%20%
Net Profit2741514341439465142565864
EPS in Rs2.230.321.221.152.791.203.243.834.293.544.634.825.33
Raw PDF

Earnings

EResults dates & reactions
No upcoming results date on calendar.

Fresh quarters land in the Financials table above, tagged NSE until screener catches up.

No reaction history yet.
No quarterly filings ingested yet.

Corporate actions

CLast 6 months

No recent corporate actions

Dividends, splits, and bonuses in the last six months show up here.

Shareholding

Sas of Mar 2026
40.22%Promoter
Promoters40.22%0.07
FIIs15.53%1.30
DIIs27.82%1.24
Public16.41%0.14
Ownership trend

Peers

P2 companies
NameCMPP/EMkt CapDiv YldNP QtrQtr Profit VarSales QtrQtr Sales VarROCE
Medplus Health₹806.9544.149,6960.00%64+24.62%1,864+23.50%12.65%
Entero Healthcar₹1,231.1044.755,3410.00%45+9.03%1,910+42.63%10.55%
Median: 2 Co.₹1,019.0244.457,5180.00%55+16.82%1,887+33.06%11.60%

Filings

D
Annual reports5
Financial Year 2025bseFinancial Year 2024bseFinancial Year 2023bseFinancial Year 2022bseFinancial Year 2022nse
Concall transcripts42
TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025TranscriptAug 2025PPTAug 2025RECAug 2025TranscriptMay 2025PPTMay 2025RECMay 2025TranscriptFeb 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024RECNov 2024TranscriptAug 2024PPTAug 2024TranscriptMay 2024PPTMay 2024TranscriptFeb 2024
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 50m - MedPlus will host an earnings call for Q1 FY2027 results on July 22, 2026 at 16:00 IST.Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (LODR) Regulations, 2015 1h - Subsidiary received three drug license suspension orders in Karnataka; potential revenue loss up to Rs 1.59 lakh.Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of SEBI (LODR) Regulations, 2015 ("SEBI LODR ") 7 Jul - Board meeting on July 21, 2026 to approve Q1 FY27 standalone and consolidated results; trading window closed July 1-23.Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (LODR) Regulations, 2015 5 Jul - Subsidiary Optival’s Nashik store drug licence suspended for five days; estimated revenue loss Rs 0.75 lakh.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 2 Jul - Submitted Regulation 74(5) certificate for quarter ended June 30, 2026.